New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareAdamax vs Tirzepatide

Adamax vs Tirzepatide

Side-by-side comparison of key properties, dosing, and research.

Cognitive Enhancement
Adamax
GLP-1 / Weight Loss Agonists
Tirzepatide
Summary
Adamax is a synthetic neuropeptide related to brain-derived neurotrophic factor (BDNF) signaling pathways. It is explored for cognitive enhancement, neuroprotection, and mood support, with proposed mechanisms involving TrkB receptor activation and enhancement of neuroplasticity similar to endogenous BDNF.
Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist that produces greater weight loss than semaglutide in head-to-head trials. SURMOUNT-1 trial showed average 21% body weight reduction at 72 weeks at the highest dose. Marketed as Mounjaro (diabetes) and Zepbound (obesity).
Half-Life
Estimated 1-3 hours (short; peptide degradation)
~5 days
Admin Route
Subcutaneous, Intranasal (research)
SubQ
Research
Typical Dose
200-400 mcg per dose
2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg
Frequency
Once daily or every other day
Once weekly, subcutaneous
Key Benefits
  • Proposed enhancement of learning and memory consolidation
  • Neuroprotective via BDNF-TrkB pathway support
  • May improve mood and resilience to stress
  • Potential support for neurogenesis
  • Cognitive clarity and focus enhancement (reported anecdotally)
  • Explored for neurodegeneration and age-related cognitive decline
  • Average 21% body weight reduction at highest dose (SURMOUNT-1)
  • Superior to semaglutide in head-to-head SURPASS trials
  • Dual GIP/GLP-1 mechanism for enhanced metabolic control
  • Significant reduction in HbA1c for type 2 diabetes
  • Improved cardiovascular risk markers
  • Reduces visceral fat preferentially
  • FDA-approved for T2DM (Mounjaro) and obesity (Zepbound)
  • Weekly dosing
Side Effects
  • Limited human safety data; largely anecdotal reports
  • Possible headache or mild overstimulation
  • Sleep disruption with late-day dosing
  • Unknown long-term safety profile
  • Nausea (most common during titration)
  • Vomiting
  • Diarrhea or constipation
  • Abdominal pain
  • +3 more
Stacks With